证券代码：301371 证券简称：敷尔佳 公告编号：2025-019 哈尔滨敷尔佳科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 年度利润分配预案的议案》，同意公司以总股本 400,080,000 股为基数，向全体在 册股东按每 10 股派发现金股利 10 元人民币（含税），合计派发现金股利 年度分配，本年度不送红股。本次预案经股东会审议通过之日至利润分配方案实施 日，公司股本如发生变动，公司将按照分配比例不变的原则对分配总额进行相应调 整。 致。 二、本次实施的权益分派方案 本公司 2024 年年度权益分派方案为： 以公司现有总股本 400,080,000 股为基数， 向全体股东每 10 股派 10.000000 元人民币现金（含税；扣税后，通过深股通持有股 份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限售股的个人 和证券投资基金每 10 股派 9.000000 元；持有首发后限售股、股权激励限售股及无 限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所得税， 待个人转让股票时，根据其持股期限计算应 ...

关于哈尔滨敷尔佳科技股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：敷尔佳 | | --- | --- | | 保荐代表人姓名：鄢凯红 | 联系电话：010-6083-8304 | | 保荐代表人姓名：范新亮 | 联系电话：010-6083-4190 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | | 是，根据敷尔佳2024年度内控自我评价报告、 | | （2）公司是否有效执行相关规章制度 | 2024年度内部控制审计报告，发行人有效执行 | | | 了相关规章制度。 | | 3.募集资金监督情况 | | | | 保荐人每月查询公司募集资金 ...

哈尔滨敷尔佳科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 14 日召开的 2024 年年度股东会审议通过，现将权 益分派事宜公告如下： 一、股东会审议通过权益分派方案的情况 1、公司于 2025 年 5 月 14 日召开 2024 年年度股东会，审议通过了《关于 2024 年度利润分配预案的议案》，同意公司以总股本 400,080,000 股为基数，向全体在 册股东按每 10 股派发现金股利 10 元人民币（含税），合计派发现金股利 400,080,000.00 元（含税），以资本公积向全体股东每 10 股转增 3 股，共计转增 120,024,000 股，转增后公司总股本为 520,104,000 股，剩余未分配利润结转以后 年度分配，本年度不送红股。本次预案经股东会审议通过之日至利润分配方案实施 日，公司股本如发生变动，公司将按照分配比例不变的原则对分配总额进行相应调 整。 2、本次权益 ...

Core Insights - The analysis focuses on the financial performance of 17 representative listed companies in the daily chemical skincare industry, highlighting the significant disparity between sales gross margin and net profit margin [1][2]. Group 1: Financial Performance - In 2024, nearly 80% of the selected companies reported a sales gross margin exceeding 50%, with some companies achieving gross margins over 75% [1][2]. - The industry shows a trend of high gross margins but low net profit margins, with 70% of companies having net profit margins below 15% [1][2]. - The top three companies in terms of sales gross margin are Jinbo Biological (92.02%), Juzhi Biological (82.09%), and Fulejia (81.73%) [2]. Group 2: Sales Net Margin Analysis - The leading companies in sales net margin are Jinbo Biological (50.68%), Juzhi Biological (37.22%), and Fulejia (32.78%) [4]. - Companies such as Jiaheng Household Chemicals (-2.57%), Shanghai Household Chemicals (-14.67%), and Yixian E-commerce (-20.9%) exhibit significantly low net profit margins [4]. Group 3: Industry Challenges - The high sales expenses in the daily chemical skincare industry are identified as a primary reason for the low net profit margins, as substantial marketing costs erode profits [2]. - Qing Song Co. has the lowest sales gross margin at 17.42%, attributed to its positioning as an OEM, facing intense competition from thousands of domestic cosmetic OEMs [6]. - Yixian E-commerce's negative net profit margin of -20.9% is linked to ongoing losses and high marketing expenditures [6].

证券代码：301371 证券简称：敷尔佳 公告编号：2025-018 哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 3、召开方式：现场表决与网络投票相结合的方式。 4、召集人：公司董事会 5、主持人：公司董事长张立国先生 6、会议召开的合法、合规性：本次股东会的召集、召开及表决方式符合《中华 人民共和国公司法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规 则》等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 1 （一）会议召开情况 1、召开时间 （1）现场会议召开时间：2025 年 5 月 14 日（星期三）下午 14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 14 日的交易时间，即上午 9：15-9：25、9:30-11:30 和下午 13:00-15:00； 通过深圳证券交易所互联网投票 ...

北京市中伦（深圳）律师事务所 关于哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年五月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing o • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（深圳）律师事务所 关于哈尔滨敷尔佳科技股份有限公司 2024 年年度股东会的 法律意见书 致：哈尔滨敷尔佳科技股份有限公司 北京市中伦（深圳）律师事务所（下称"本所"）接受哈尔滨敷尔佳科技股 份有限公司（下称"公司"）的委托，指派律师出席公司 2024 年年度股东会（下 称"本次股东会"），并根据《中华人民共和 ...

Core Insights - The performance of domestic beauty companies in China is showing significant divergence, with some achieving remarkable growth while others face declines, indicating a reshaping of the market landscape [1][4][42] Group 1: Company Performance - Proya has become the first domestic beauty company to enter the 10 billion yuan club, with a revenue of 10.778 billion yuan, growing by 21.04% [2] - Other companies like Shangmei and Juzi Biological also reported substantial revenue increases of 62.08% and 57.17% respectively, while Shanghai Jahwa experienced a revenue decline of 13.93% [2][3] - Six beauty companies have revenues exceeding 5 billion yuan, suggesting that this threshold will soon become a significant benchmark for the top 10 domestic beauty brands [1] Group 2: Profitability Trends - Juzi Biological leads in profitability with a profit of 2.062 billion yuan, up 42.06%, while Proya's profit reached 1.552 billion yuan, growing by 30% [3] - In contrast, Shanghai Jahwa reported a loss of 833 million yuan, marking a 266.60% decline, highlighting the stark differences in profitability among companies [3][11] Group 3: Market Dynamics - The current market dynamics indicate a shift towards efficacy-driven products, with companies that successfully launched standout products seeing better performance [4][5] - The competition is intensifying, with new entrants emerging and established brands needing to adapt to changing consumer preferences and market trends [7][30] Group 4: R&D and Strategic Focus - Companies are increasingly focusing on R&D, with most reporting a rise in R&D expenditures, indicating a strategic shift towards innovation and efficacy [20][21] - The trend of acquisitions and investments in technology is becoming a key strategy for companies aiming to enhance market share and scale [23][24] Group 5: Emerging Opportunities - The male skincare market is growing rapidly, presenting new opportunities for brands to capture this segment [36] - The aging population is creating demand for products targeting older consumers, which remains largely untapped [39] - As online sales plateau, brands are shifting focus to offline channels, indicating a potential new battleground for market share [40]

Group 1 - The A-share market saw a rapid rise in PEEK material concept stocks, indicating strong investor interest in this sector [1] - Zhongxin Fluorine Materials hit the daily limit up, showcasing significant market momentum [1] - Newhan New Materials and Fuheng New Materials both increased by over 5%, reflecting positive market sentiment [1] - Zhongyan Co. and Jusa Long also experienced gains, indicating a broader trend in the industry [1]

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. (Fulejia) has experienced a significant decline in revenue and profit in Q1 2025, indicating ongoing challenges in its business operations and profitability metrics [2][4][10]. Financial Performance - In Q1 2025, Fulejia's revenue dropped by 26.39% year-on-year to 301 million yuan, with net profit falling nearly 40% to 91.38 million yuan [2]. - For the full year 2024, Fulejia reported a revenue increase of 4.32% to 2.017 billion yuan, but net profit decreased by 11.77% to 661 million yuan, and non-recurring net profit fell by 17% to 604 million yuan [5][10]. - The company's cash flow from operating activities turned negative for the first time, with a year-on-year decline of 151.78% [2]. Marketing and Sales Strategy - Fulejia's sales expense ratio surged from 5.72% to 52.89% over recent years, with marketing expenses in 2024 reaching 748 million yuan, exceeding net profit for the same period [5][6]. - Online direct sales accounted for 54.96% of total revenue in 2024, but the cost of acquiring customers online has increased, leading to a decrease in gross margin [6][7]. - The average price of Fulejia's cosmetic products fell from 40.99 yuan in 2023 to 34.82 yuan in 2024, indicating a decline in product pricing power [8]. Inventory and Production - Fulejia's inventory turnover days doubled to 307 days, with inventory levels increasing by 40.75% year-on-year, reflecting production outpacing sales [3][13]. - The company produced 21.386 million standard units in 2024, while sales were only 20.396 million units, leading to excess inventory [15]. Research and Development - Fulejia's investment in research and development is significantly lower compared to sales expenses, with a ratio of 21:1 in 2024, which has increased by 180% since 2021 [3][16]. - The focus on marketing over R&D raises concerns about the company's long-term competitive advantage in a challenging market environment [16].

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. is demonstrating resilience and potential in the competitive medical beauty skincare market, focusing on precise consumer demand and diversified market expansion [2] Group 1: Market Performance - In 2024, Fulejia achieved operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32% [2] - Online sales reached 1.108 billion yuan in 2024, growing by 20.03% year-on-year, with strong performance during promotional events [3] Group 2: R&D and Innovation - R&D expenses increased by 6.04% in 2024, with the number of R&D personnel growing by 114.81% [3] - The completion of a self-owned production base and the establishment of a Shanghai R&D center in 2024 signify a strengthened R&D capability [3] Group 3: Shareholder Returns and Strategic Adjustments - Fulejia announced its first dividend in May 2024, with plans for another before the Spring Festival in early 2025, aiming to enhance stock liquidity [4] - The company is optimizing sales channel structures and strengthening product pricing management for long-term sustainable development [4][5] Group 4: Competitive Advantage - The acquisition of Harbin Beixing Pharmaceutical Co., Ltd. has provided Fulejia with independent production capabilities, laying a solid foundation for long-term growth [5] - The company aims to leverage its comprehensive competitive advantages in R&D, products, branding, resources, and market to enhance its position in the medical beauty skincare sector [5]